系统性硬化症成人患者的回避或限制性食物摄入障碍症状:西班牙全国性研究
本研究采用西班牙全国横断面网络调查,纳入200例系统性硬化症(SSc)患者,评估回避或限制性食物摄入障碍(ARFID)症状、胃肠道症状负担与健康相关生活质量。结果显示99例(49.5%)患者ARFID筛查阳性,阳性者中53例基于对进食不良后果的恐惧而阳性;ARFID症状与UCLA GIT 2.0总分中度相关(r=0.408,P<0.001),与SF-12各领域及躯体、心理成分均相关(均P<0.05)。作者认为ARFID症状在SSc患者中相对常见,未来需研究阳性筛查反映的是对疾病的适应性反应还是需要行为治疗的病理性限制。
要点
- 200例SSc患者中99例(49.5%)ARFID筛查阳性。
- 阳性者中53例因对进食不良后果(如胃肠道不适)的恐惧而阳性。
- ARFID症状与UCLA GIT 2.0总分中度相关(r=0.408,P<0.001)。
核心结论
- ARFID症状在SSc患者中相对常见。
- 未来研究需明确ARFID筛查阳性反映的是对疾病的适应性反应,还是需要行为治疗的病理性限制。
研究设计与样本
- 西班牙全国横断面网络调查。
- 200例系统性硬化症(SSc)患者完成西班牙语九条目ARFID筛查量表、UCLA SCTC GIT 2.0胃肠道症状负担评估及SF-12健康相关生活质量评估。
主要发现
- 200例SSc患者中99例(49.5%)ARFID筛查阳性。
- ARFID筛查阳性者中53例基于对进食不良后果(如胃肠道不适)的恐惧而筛查阳性。
- ARFID筛查阳性与自我报告的肠内营养、体重下降及自行(相较医疗提供者监测)饮食限制的频率更高相关。
- ARFID症状与UCLA GIT 2.0总分中度相关(r=0.408,P<0.001),与反流分量表(r=0.058,P=0.420)及便秘分量表(r=0.090,P=0.209)无显著相关。
- ARFID症状与SF-12所有领域及躯体、心理成分的健康相关生活质量较差相关(均P<0.05)。
关键数值与推荐
- ARFID筛查阳性:200例中99例(49.5%)。
- 基于对进食不良后果恐惧的ARFID筛查阳性:99例中53例。
- ARFID症状与UCLA GIT 2.0总分:r=0.408,P<0.001;反流分量表:r=0.058,P=0.420;便秘分量表:r=0.090,P=0.209。
- ARFID症状与SF-12躯体及心理成分:均P<0.05。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Patients with systemic sclerosis (SSc) may restrict food intake to manage their symptoms (particularly gastrointestinal [GI]). Whether some patients may develop nutritional and/or quality-of-life impairments indicative of an eating disorder, avoidant or restrictive food intake disorder (ARFID), is unknown. We aimed to (1) identify the prevalence and characteristics of ARFID symptoms in patients with SSc and (2) explore the relationship among ARFID symptoms, GI symptom burden, and health-related quality of life. METHODS: In a cross-sectional internet survey nationwide in Spain, patients with SSc completed the Spanish Nine-Item ARFID Screen and assessments of gastrointestinal symptom burden (University of California Los Angeles Scleroderma Clinical Trial Consortium GI tract 2.0 [UCLA SCTC GIT 2.0]) and health-related quality of life (12-item Short Form Survey [SF-12]). RESULTS: Of 200 patients with SSc, 99 patients (49.5%) screened positive for ARFID. Just over half of those who screened positive for ARFID (n = 53) screened positive based on having a fear of aversive consequences around eating (eg, GI discomfort). A positive ARFID screen was associated with a greater frequency of self-reported enteral nutrition, weight loss, and self-initiated (vs provider-monitored) diet restrictions. ARFID symptoms were moderately associated with worse GI symptom severity by UCLA GIT 2.0 total score (r = 0.408, P < 0.001) but not for the reflux subscale (r = 0.058, P = 0.420) and constipation subscale (r = 0.090, P = 0.209) and with worse health-related quality of life in all domains and both the physical and mental components of the SF-12 (all P < 0.05). CONCLUSION: ARFID symptoms were relatively common in patients with SSc. Future research is needed to identify when a positive screen for ARFID reflects an adaptive response to disease or pathologic restriction indicative of ARFID warranting behavioral treatment.
引用
- Alcala-Gonzalez LG, Burton-Murray H, Atkins M, et al. Avoidant or Restrictive Food Intake Disorder Symptoms in Adults With Systemic Sclerosis: A Nationwide Study in Spain. Arthritis Care Res (Hoboken). 2025. PMID: 40356227. doi:10.1002/acr.25569
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。